丰原药业(000153) - 2024 Q2 - 季度财报

Financial Performance - The company's operating revenue for the reporting period was ¥2,307,876,468.11, representing a 0.98% increase compared to ¥2,285,417,858.93 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥100,212,492.64, a decrease of 2.72% from ¥103,015,799.31 in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥85,638,373.28, down 2.71% from ¥88,022,630.07 in the same period last year[10]. - The net cash flow from operating activities was ¥32,511,792.92, a significant decrease of 28.45% compared to ¥45,436,607.43 in the previous year[10]. - The basic earnings per share were ¥0.2156, down 2.71% from ¥0.3102 in the same period last year[10]. - Operating profit was 134.72 million yuan, a decrease of 5.72% year-on-year[15]. - Total profit amounted to 135.55 million yuan, down 5.57% from the previous year[15]. - The company recognized equity-settled share-based payment expenses of 7.31 million yuan during the reporting period[15]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,717,619,543.83, an increase of 7.43% from ¥4,391,320,148.20 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company were ¥1,948,734,920.28, reflecting a 3.14% increase from ¥1,889,409,585.59 at the end of the previous year[10]. - Total liabilities increased to CNY 2,740,826,458.68 from CNY 2,472,494,405.67, representing a rise of approximately 10.8%[92]. - The company's equity increased to CNY 1,976,793,085.15 from CNY 1,918,825,742.53, showing a growth of approximately 3.0%[92]. Revenue Sources - The revenue from pharmaceutical manufacturing was ¥919,493,685.30, a decrease of 17.09% from ¥1,109,065,934.59, while revenue from pharmaceutical retail increased by 18.62% to ¥1,348,327,577.99[24]. - The company reported a significant increase in other income, which rose by 129.28% to ¥35,808,574.79, primarily due to increased government subsidies[23]. - The investment income surged by 27,682.71% to ¥4,009,134.25, attributed to received investment dividends[23]. Cash Flow - The company's cash and cash equivalents decreased by 33.16% to ¥-74,496,445.33, compared to ¥-111,448,232.56 in the previous year[23]. - Cash flow from operating activities generated a net cash inflow of CNY 32,511,792.92, down from CNY 45,436,607.43 in the first half of 2023[101]. - The cash flow from investing activities resulted in a net outflow of CNY 130,926,486.72, compared to a net outflow of CNY 72,830,062.01 in the same period last year[101]. - Cash flow from financing activities generated a net inflow of CNY 23,794,892.37, a recovery from a net outflow of CNY 84,242,501.39 in the first half of 2023[101]. Shareholder Information - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.79% of shares, totaling 50,178,992 shares, with an increase of 14,336,855 shares during the reporting period[79]. - The second-largest shareholder, Bengbu Tushan Enterprise Management Co., Ltd., holds 7.69% of shares, totaling 35,730,660 shares, with an increase of 10,208,760 shares[79]. - The total number of shares held by the top 10 shareholders increased significantly, indicating a consolidation of ownership[79]. Research and Development - The company emphasizes new drug research and development, holding multiple national first and second category new drug varieties[15]. - Research and development expenses decreased by 36.31% to ¥26,360,784.48, indicating a reduction in investment in new product development[23]. Environmental Compliance - The company is compliant with various environmental protection laws and has established waste treatment facilities to minimize ecological impact[46]. - The company has developed emergency response plans for environmental incidents, which have been submitted to environmental authorities for record[51]. - The company continues to enhance its environmental protection investments to support sustainable development[52]. Corporate Governance - The company held its first extraordinary general meeting of 2024 on February 22, with an investor participation rate of 29.29%[40]. - The annual general meeting for 2023 took place on May 22, with a participation rate of 27.08%[40]. - The company did not experience any major litigation or arbitration matters during the reporting period[62]. Taxation and Compliance - The company applies a tax rate of 25% for corporate income tax and various rates for value-added tax ranging from 3% to 13%[184]. - The company and its subsidiaries have been recognized as high-tech enterprises, enjoying a corporate income tax rate of 15% for three years starting from January 1, 2023[186]. - The company has implemented a unified tax calculation and management approach for its subsidiaries, which is expected to optimize tax efficiency[187].